Paricalcitol | List of Frontiers open access articles

Original Research

Published on 05 Feb 2019

Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison

in Translational and Clinical Endocrinology

Jacek Zawierucha
Jolanta Malyszko
Jacek S. Malyszko
Tomasz Prystacki
Wojciech P. Marcinkowski
Teresa Dryl-Rydzynska

Frontiers in Endocrinology

doi 10.3389/fendo.2019.00040

8,779 views
7 citations

Original Research

Published on 21 Jul 2021

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis

in Health Economics

Zhuolin Zhang
Lele Cai
Hong Wu
Xinglu Xu
Wenqing Fang
Xuan He
Xiao Wang
Xin Li

Frontiers in Public Health

doi 10.3389/fpubh.2021.712027

8,961 views
8 citations

Original Research

Published on 24 Feb 2023

Vitamin D-VDR (vitamin D receptor) alleviates glucose metabolism reprogramming in lipopolysaccharide-induced acute kidney injury

in Renal Physiology and Pathophysiology

Qing Dai
Hao Zhang
Shiqi Tang
Xueqin Wu
Jianwen Wang
Bin Yi
Jishi Liu
Zhi Li
Qin Liao
Aimei Li

Frontiers in Physiology

doi 10.3389/fphys.2023.1083643

4,165 views
10 citations

Systematic Review

Published on 15 Oct 2021

Vitamin D Analogs Can Retard the Onset or Progression of Diabetic Kidney Disease: A Systematic Review

in Diabetes Nephropathy

Samuel N. Uwaezuoke

Frontiers in Clinical Diabetes and Healthcare

doi 10.3389/fcdhc.2021.763844

3,403 views
4 citations

Original Research

Published on 03 Apr 2025

Paricalcitol alleviates intestinal ischemia-reperfusion injury via inhibition of the ATF4-CHOP pathway

in Gastrointestinal and Hepatic Pharmacology

Jiawei Zhang
Tingting Liu
Tongqing Xue
Zhongzhi Jia

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1529343

1,003 views

Original Research

Published on 16 Oct 2017

Experimental Autoimmune Encephalomyelitis Is Successfully Controlled by Epicutaneous Administration of MOG Plus Vitamin D Analog

in Immunological Tolerance and Regulation

Sofia Fernanda Gonçalves Zorzella-Pezavento
Luiza Ayumi Nishiyama Mimura
Thais Fernanda Campos Fraga-Silva
Larissa Lumi Watanabe Ishikawa
Thais Graziela Donegá França
Alexandrina Sartori

Frontiers in Immunology

doi 10.3389/fimmu.2017.01198

6,778 views
14 citations

Original Research

Published on 26 Jul 2024

Vitamin D/vitamin D receptor protects intestinal barrier against colitis by positively regulating Notch pathway

in Gastrointestinal and Hepatic Pharmacology

Yanni Li
Yaoyu Guo
Chong Geng
Shuailing Song
Wenjuan Yang
Xiao Li
Chunhui Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1421577

2,463 views
3 citations

Articles

Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis

Vitamin D-VDR (vitamin D receptor) alleviates glucose metabolism reprogramming in lipopolysaccharide-induced acute kidney injury

Vitamin D Analogs Can Retard the Onset or Progression of Diabetic Kidney Disease: A Systematic Review

Paricalcitol alleviates intestinal ischemia-reperfusion injury via inhibition of the ATF4-CHOP pathway

Experimental Autoimmune Encephalomyelitis Is Successfully Controlled by Epicutaneous Administration of MOG Plus Vitamin D Analog

Vitamin D/vitamin D receptor protects intestinal barrier against colitis by positively regulating Notch pathway